[go: up one dir, main page]

WO2005090387A3 - Histone h2a peptide derivatives and analogs and methods of use thereof - Google Patents

Histone h2a peptide derivatives and analogs and methods of use thereof Download PDF

Info

Publication number
WO2005090387A3
WO2005090387A3 PCT/IL2005/000328 IL2005000328W WO2005090387A3 WO 2005090387 A3 WO2005090387 A3 WO 2005090387A3 IL 2005000328 W IL2005000328 W IL 2005000328W WO 2005090387 A3 WO2005090387 A3 WO 2005090387A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
protecting against
methods
histone
analogs
Prior art date
Application number
PCT/IL2005/000328
Other languages
French (fr)
Other versions
WO2005090387A2 (en
Inventor
Uri Wormser
Original Assignee
Univ Jerusalem Yissum Res Dev
Uri Wormser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jerusalem Yissum Res Dev, Uri Wormser filed Critical Univ Jerusalem Yissum Res Dev
Publication of WO2005090387A2 publication Critical patent/WO2005090387A2/en
Publication of WO2005090387A3 publication Critical patent/WO2005090387A3/en
Priority to US11/527,162 priority Critical patent/US7528227B2/en
Priority to US11/750,408 priority patent/US7605132B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptides derived from a segment of human histone H2A, the segment corresponding to amino acid residues 36-44 of human histone H2A, are capable of reducing or ameliorating the extent of injury induced by noxious stimuli when administered to animals. Pharmaceutical compositions and methods of using these peptides are also disclosed. The pharmaceutical compositions according to the invention are useful for treating and protecting against inflammatory diseases, autoimmune diseases, for treating and protecting against tissue damage, and for inhibiting metalloproteinase activity, and for treating and protecting against diseases associated with the breakdown of extracellular matrix or connective tissues.
PCT/IL2005/000328 2001-08-29 2005-03-23 Histone h2a peptide derivatives and analogs and methods of use thereof WO2005090387A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/527,162 US7528227B2 (en) 2004-03-23 2006-09-25 Histone H2A peptide derivatives and uses thereof
US11/750,408 US7605132B2 (en) 2001-08-29 2007-05-18 Protective factors against inflammation, burns and noxious stimuli

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55533404P 2004-03-23 2004-03-23
US60/555,334 2004-03-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/527,162 Continuation-In-Part US7528227B2 (en) 2001-08-29 2006-09-25 Histone H2A peptide derivatives and uses thereof

Publications (2)

Publication Number Publication Date
WO2005090387A2 WO2005090387A2 (en) 2005-09-29
WO2005090387A3 true WO2005090387A3 (en) 2006-02-02

Family

ID=34964143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/000328 WO2005090387A2 (en) 2001-08-29 2005-03-23 Histone h2a peptide derivatives and analogs and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2005090387A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006019567D1 (en) 2005-03-22 2011-02-24 Rohto Pharma PEPTIDES THAT INCREASE COLLAGEN OR HYALURONIC ACID PRODUCTION
WO2008010218A1 (en) * 2006-07-17 2008-01-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptides derived from human histone h2a and methods of use thereof
EP2558110B1 (en) 2010-04-11 2015-06-03 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Extract and peptides derived from oryza sativa japonica group and uses thereof
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
US20130203650A1 (en) 2010-08-31 2013-08-08 Yissum Research Development Company Of The Hebrew Uviversity Of Jerusalem Polypeptides derived from alpha-1 antitrypsin and methods of use thereof
US10570174B2 (en) 2015-02-08 2020-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peptides for the treatment of malignant proliferative diseases
CN106397575A (en) * 2016-10-20 2017-02-15 上海懿贝瑞生物医药科技有限公司 Preparation method and application of polypeptide with ectoenzyme histone toxicity inhibition function
CN112745379A (en) * 2021-01-22 2021-05-04 浙江辉肽生命健康科技有限公司 Bioactive peptide with amino acid structure RDNKKTRIIPR, and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489577A1 (en) * 1990-12-03 1992-06-10 Celltech Limited Peptidyl derivatives
WO1998009985A2 (en) * 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides and uses thereof
WO2003017920A2 (en) * 2001-08-29 2003-03-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
EP1297753A1 (en) * 2001-10-01 2003-04-02 Societe Des Produits Nestle S.A. Flavour-active peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489577A1 (en) * 1990-12-03 1992-06-10 Celltech Limited Peptidyl derivatives
WO1998009985A2 (en) * 1996-09-03 1998-03-12 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides and uses thereof
WO2003017920A2 (en) * 2001-08-29 2003-03-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
EP1297753A1 (en) * 2001-10-01 2003-04-02 Societe Des Produits Nestle S.A. Flavour-active peptides

Also Published As

Publication number Publication date
WO2005090387A2 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
RU2007131504A (en) PEPTIDES HAVING AGONISTIC ACTIVITY AGAINST THE NEUROPEPTIDE-2- (Y2R) RECEPTOR
RS20050530A (en) Binding agents which inhibit myostatin
UA100222C2 (en) Tissue protective peptides and uses thereof
TR199800258T1 (en) New opioid peptides.
BRPI0519124A2 (en) compound, method for treating, preventing or ameliorating obesity and related diseases and / or symptoms thereof, pharmaceutical composition, compound use, and combination
WO2005090387A3 (en) Histone h2a peptide derivatives and analogs and methods of use thereof
WO2010005580A3 (en) Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
KR20170138547A (en) Short synthetic peptide for treatment and/or prophylaxis of autoimmune and inflammatory disorders
WO2004009625A3 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES
NO20060675L (en) Enhanced recombinant human interferon beta-lb polypeptides
AR044209A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE EPINASTINE FOR THE TREATMENT OF SKIN DISEASES
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
WO2005089803A3 (en) Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
CA2940751C (en) Uses of an angiotensin (1-7) peptide for the delayed treatment of stroke
WO2010086867A3 (en) Peptides, pharmaceutical compositions comprising same and uses thereof
RU2537560C2 (en) Tetrapeptide and preparation, possessing cerebroprotective and antiamnestic activities (versions)
US20240182524A1 (en) Cyclic peptidomimetic for the treatment of neurological disorders
WO2007139433A8 (en) Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application
BRPI0418017A (en) medicament comprising long ptx3 pentraxin inhibitors
EP2308837A3 (en) Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors
WO2003017920A3 (en) Protective factors against inflammation, burns and noxious stimuli
YU60199A (en) New bpc peptide salts with organo-protective activity,the process for their preparation and their use in therapy
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11527162

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 11527162

Country of ref document: US

122 Ep: pct application non-entry in european phase